Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 107


Identification of pharmacodynamic biomarkers and common molecular mechanisms of response to genotoxic agents in cancer cell lines.

Min DJ, Zhao Y, Monks A, Palmisano A, Hose C, Teicher BA, Doroshow JH, Simon RM.

Cancer Chemother Pharmacol. 2019 Jul 31. doi: 10.1007/s00280-019-03898-z. [Epub ahead of print]


The NCI Transcriptional Pharmacodynamics Workbench: A Tool to Examine Dynamic Expression Profiling of Therapeutic Response in the NCI-60 Cell Line Panel.

Monks A, Zhao Y, Hose C, Hamed H, Krushkal J, Fang J, Sonkin D, Palmisano A, Polley EC, Fogli LK, Konaté MM, Miller SB, Simpson MA, Voth AR, Li MC, Harris E, Wu X, Connelly JW, Rapisarda A, Teicher BA, Simon R, Doroshow JH.

Cancer Res. 2018 Dec 15;78(24):6807-6817. doi: 10.1158/0008-5472.CAN-18-0989. Epub 2018 Oct 24.


Making the mast of a rainy day: environmental constraints can synchronize mass seeding across populations.

Tanentzap AJ, Monks A.

New Phytol. 2018 Jul;219(1):6-8. doi: 10.1111/nph.15219. No abstract available.


Longitudinal Transcriptional Response of Glycosylation-Related Genes, Regulators, and Targets in Cancer Cell Lines Treated With 11 Antitumor Agents.

Krushkal J, Zhao Y, Hose C, Monks A, Doroshow JH, Simon R.

Cancer Inform. 2017 Dec 15;16:1176935117747259. doi: 10.1177/1176935117747259. eCollection 2017.


Characterization of potent and selective iodonium-class inhibitors of NADPH oxidases.

Lu J, Risbood P, Kane CT Jr, Hossain MT, Anderson L, Hill K, Monks A, Wu Y, Antony S, Juhasz A, Liu H, Jiang G, Harris E, Roy K, Meitzler JL, Konaté M, Doroshow JH.

Biochem Pharmacol. 2017 Nov 1;143:25-38. doi: 10.1016/j.bcp.2017.07.007. Epub 2017 Jul 11.


Mechanical Harvesting Effectively Controls Young Typha spp. Invasion and Unmanned Aerial Vehicle Data Enhances Post-treatment Monitoring.

Lishawa SC, Carson BD, Brandt JS, Tallant JM, Reo NJ, Albert DA, Monks AM, Lautenbach JM, Clark E.

Front Plant Sci. 2017 Apr 25;8:619. doi: 10.3389/fpls.2017.00619. eCollection 2017.


Optimizing MRI Logistics: Focused Process Improvements Can Increase Throughput in an Academic Radiology Department.

O'Brien JJ, Stormann J, Roche K, Cabral-Goncalves I, Monks A, Hallett D, Mortele KJ.

AJR Am J Roentgenol. 2017 Feb;208(2):W38-W44. doi: 10.2214/AJR.16.16680. Epub 2016 Dec 8.


Small Cell Lung Cancer Screen of Oncology Drugs, Investigational Agents, and Gene and microRNA Expression.

Polley E, Kunkel M, Evans D, Silvers T, Delosh R, Laudeman J, Ogle C, Reinhart R, Selby M, Connelly J, Harris E, Fer N, Sonkin D, Kaur G, Monks A, Malik S, Morris J, Teicher BA.

J Natl Cancer Inst. 2016 May 31;108(10). doi: 10.1093/jnci/djw122. Print 2016 Oct.


Resource limitation underlying multiple masting models makes mast seeding sensitive to future climate change.

Monks A, Monks JM, Tanentzap AJ.

New Phytol. 2016 Apr;210(2):419-30. doi: 10.1111/nph.13817. Epub 2016 Jan 4.


Bromodomain and hedgehog pathway targets in small cell lung cancer.

Kaur G, Reinhart RA, Monks A, Evans D, Morris J, Polley E, Teicher BA.

Cancer Lett. 2016 Feb 28;371(2):225-39. doi: 10.1016/j.canlet.2015.12.001. Epub 2015 Dec 10.


Antitumour benzothiazoles. Part 32: DNA adducts and double strand breaks correlate with activity; synthesis of 5F203 hydrogels for local delivery.

Stone EL, Citossi F, Singh R, Kaur B, Gaskell M, Farmer PB, Monks A, Hose C, Stevens MF, Leong CO, Stocks M, Kellam B, Marlow M, Bradshaw TD.

Bioorg Med Chem. 2015 Nov 1;23(21):6891-9. doi: 10.1016/j.bmc.2015.09.052. Epub 2015 Oct 3.


Sarcoma Cell Line Screen of Oncology Drugs and Investigational Agents Identifies Patterns Associated with Gene and microRNA Expression.

Teicher BA, Polley E, Kunkel M, Evans D, Silvers T, Delosh R, Laudeman J, Ogle C, Reinhart R, Selby M, Connelly J, Harris E, Monks A, Morris J.

Mol Cancer Ther. 2015 Nov;14(11):2452-62. doi: 10.1158/1535-7163.MCT-15-0074. Epub 2015 Sep 8.


Metrics for Radiologists in the Era of Value-based Health Care Delivery.

Sarwar A, Boland G, Monks A, Kruskal JB.

Radiographics. 2015 May-Jun;35(3):866-76. doi: 10.1148/rg.2015140221. Epub 2015 Apr 3. Review.


Bioenergetic properties of human sarcoma cells help define sensitivity to metabolic inhibitors.

Issaq SH, Teicher BA, Monks A.

Cell Cycle. 2014;13(7):1152-61. doi: 10.4161/cc.28010. Epub 2014 Feb 10.


Cediranib for metastatic alveolar soft part sarcoma.

Kummar S, Allen D, Monks A, Polley EC, Hose CD, Ivy SP, Turkbey IB, Lawrence S, Kinders RJ, Choyke P, Simon R, Steinberg SM, Doroshow JH, Helman L.

J Clin Oncol. 2013 Jun 20;31(18):2296-302. doi: 10.1200/JCO.2012.47.4288. Epub 2013 Apr 29.


A small molecule (pluripotin) as a tool for studying cancer stem cell biology: proof of concept.

Mertins SD, Scudiero DA, Hollingshead MG, Divelbiss RD Jr, Alley MC, Monks A, Covell DG, Hite KM, Salomon DS, Niederhuber JE.

PLoS One. 2013;8(2):e57099. doi: 10.1371/journal.pone.0057099. Epub 2013 Feb 21.


Identification of CBX3 and ABCA5 as putative biomarkers for tumor stem cells in osteosarcoma.

Saini V, Hose CD, Monks A, Nagashima K, Han B, Newton DL, Millione A, Shah J, Hollingshead MG, Hite KM, Burkett MW, Delosh RM, Silvers TE, Scudiero DA, Shoemaker RH.

PLoS One. 2012;7(8):e41401. doi: 10.1371/journal.pone.0041401. Epub 2012 Aug 3. Erratum in: PLoS One. 2012;7(11). doi:10.1371/annotation/8c74aaee-897d-4682-b62d-d95a3506c210.


CHEK2 genomic and proteomic analyses reveal genetic inactivation or endogenous activation across the 60 cell lines of the US National Cancer Institute.

Zoppoli G, Solier S, Reinhold WC, Liu H, Connelly JW Jr, Monks A, Shoemaker RH, Abaan OD, Davis SR, Meltzer PS, Doroshow JH, Pommier Y.

Oncogene. 2012 Jan 26;31(4):403-18. doi: 10.1038/onc.2011.283. Epub 2011 Jul 18. Erratum in: Oncogene. 2012 Jan 26;31(4):535-6.


Adaphostin toxicity in a sensitive non-small cell lung cancer model is mediated through Nrf2 signaling and heme oxygenase 1.

Fer ND, Shoemaker RH, Monks A.

J Exp Clin Cancer Res. 2010 Jul 9;29:91. doi: 10.1186/1756-9966-29-91.


Development of antiproliferative phenylmaleimides that activate the unfolded protein response.

Muus U, Hose C, Yao W, Kosakowska-Cholody T, Farnsworth D, Dyba M, Lountos GT, Waugh DS, Monks A, Burke TR Jr, Michejda CJ.

Bioorg Med Chem. 2010 Jun 15;18(12):4535-41. doi: 10.1016/j.bmc.2010.04.057. Epub 2010 Apr 24.


Cellular inhibition of checkpoint kinase 2 (Chk2) and potentiation of camptothecins and radiation by the novel Chk2 inhibitor PV1019 [7-nitro-1H-indole-2-carboxylic acid {4-[1-(guanidinohydrazone)-ethyl]-phenyl}-amide].

Jobson AG, Lountos GT, Lorenzi PL, Llamas J, Connelly J, Cerna D, Tropea JE, Onda A, Zoppoli G, Kondapaka S, Zhang G, Caplen NJ, Cardellina JH 2nd, Yoo SS, Monks A, Self C, Waugh DS, Shoemaker RH, Pommier Y.

J Pharmacol Exp Ther. 2009 Dec;331(3):816-26. doi: 10.1124/jpet.109.154997. Epub 2009 Sep 9.


Gene expression-signature of belinostat in cell lines is specific for histone deacetylase inhibitor treatment, with a corresponding signature in xenografts.

Monks A, Hose CD, Pezzoli P, Kondapaka S, Vansant G, Petersen KD, Sehested M, Monforte J, Shoemaker RH.

Anticancer Drugs. 2009 Sep;20(8):682-92. doi: 10.1097/CAD.0b013e32832e14e1.


Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies.

Kummar S, Kinders R, Gutierrez ME, Rubinstein L, Parchment RE, Phillips LR, Ji J, Monks A, Low JA, Chen A, Murgo AJ, Collins J, Steinberg SM, Eliopoulos H, Giranda VL, Gordon G, Helman L, Wiltrout R, Tomaszewski JE, Doroshow JH.

J Clin Oncol. 2009 Jun 1;27(16):2705-11. doi: 10.1200/JCO.2008.19.7681. Epub 2009 Apr 13.


Growth inhibition of hepatocellular carcinoma cells in vitro and in vivo by the 8-methoxy analog of WMC79.

Kosakowska-Cholody T, Cholody WM, Hariprakasha HK, Monks A, Kar S, Wang M, Michejda CJ, Carr BI.

Cancer Chemother Pharmacol. 2009 Apr;63(5):769-78. doi: 10.1007/s00280-008-0801-z. Epub 2008 Jul 19.


Drug-induced expression of nonsteroidal anti-inflammatory drug-activated gene/macrophage inhibitory cytokine-1/prostate-derived factor, a putative tumor suppressor, inhibits tumor growth.

Martinez JM, Sali T, Okazaki R, Anna C, Hollingshead M, Hose C, Monks A, Walker NJ, Baek SJ, Eling TE.

J Pharmacol Exp Ther. 2006 Aug;318(2):899-906. Epub 2006 May 19.


Differential gene expression as a potential classifier of 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole-sensitive and -insensitive cell lines.

Wallqvist A, Connelly J, Sausville EA, Covell DG, Monks A.

Mol Pharmacol. 2006 Mar;69(3):737-48. Epub 2005 Dec 6.


WMC-79, a potent agent against colon cancers, induces apoptosis through a p53-dependent pathway.

Kosakowska-Cholody T, Cholody WM, Monks A, Woynarowska BA, Michejda CJ.

Mol Cancer Ther. 2005 Oct;4(10):1617-27.


Echinomycin, a small-molecule inhibitor of hypoxia-inducible factor-1 DNA-binding activity.

Kong D, Park EJ, Stephen AG, Calvani M, Cardellina JH, Monks A, Fisher RJ, Shoemaker RH, Melillo G.

Cancer Res. 2005 Oct 1;65(19):9047-55.


Benzodithiophenes induce differentiation and apoptosis in human leukemia cells.

Jing Y, Hellinger N, Xia L, Monks A, Sausville EA, Zelent A, Waxman S.

Cancer Res. 2005 Sep 1;65(17):7847-55.


Elucidation of thioredoxin as a molecular target for antitumor quinols.

Bradshaw TD, Matthews CS, Cookson J, Chew EH, Shah M, Bailey K, Monks A, Harris E, Westwell AD, Wells G, Laughton CA, Stevens MF.

Cancer Res. 2005 May 1;65(9):3911-9.


Components of the cell death machine and drug sensitivity of the National Cancer Institute Cell Line Panel.

Svingen PA, Loegering D, Rodriquez J, Meng XW, Mesner PW Jr, Holbeck S, Monks A, Krajewski S, Scudiero DA, Sausville EA, Reed JC, Lazebnik YA, Kaufmann SH.

Clin Cancer Res. 2004 Oct 15;10(20):6807-20.


The experimental antitumor agents Phortress and doxorubicin are equiactive against human-derived breast carcinoma xenograft models.

Fichtner I, Monks A, Hose C, Stevens MF, Bradshaw TD.

Breast Cancer Res Treat. 2004 Sep;87(1):97-107.


Mining the NCI screening database: explorations of agents involved in cell cycle regulation.

Wallqvist A, Monks A, Rabow AA, Thanki N, Shoemaker RH, Covell DG.

Prog Cell Cycle Res. 2003;5:173-9. Review.


Preclinical models for defining efficacy of drug combinations: mapping the road to the clinic.

Gitler MS, Monks A, Sausville EA.

Mol Cancer Ther. 2003 Sep;2(9):929-32. No abstract available.


Identification of PDGFR as a receptor for AAV-5 transduction.

Di Pasquale G, Davidson BL, Stein CS, Martins I, Scudiero D, Monks A, Chiorini JA.

Nat Med. 2003 Oct;9(10):1306-12. Epub 2003 Sep 14.


Inhibition of glycogen phosphorylase (GP) by CP-91,149 induces growth inhibition correlating with brain GP expression.

Schnier JB, Nishi K, Monks A, Gorin FA, Bradbury EM.

Biochem Biophys Res Commun. 2003 Sep 12;309(1):126-34.


Nucleotide excision repair protein levels vis-à-vis anticancer drug resistance in 60 human tumor cell lines.

Chen ZP, Malapetsa A, Monks A, Myers TG, Mohr G, Sausville EA, Scudiero DA, Panasci LC.

Ai Zheng. 2002 Mar;21(3):233-9.


Correlation of nucleoside and nucleobase transporter gene expression with antimetabolite drug cytotoxicity.

Lu X, Gong S, Monks A, Zaharevitz D, Moscow JA.

J Exp Ther Oncol. 2002 Jul-Aug;2(4):200-12.


Increased expression of beta 2-microglobulin in multidrug-resistant tumour cells.

Scheffer GL, de Jong MC, Monks A, Flens MJ, Hose CD, Izquierdo MA, Shoemaker RH, Scheper RJ.

Br J Cancer. 2002 Jun 17;86(12):1943-50.


DNA repair protein levels vis-à-vis anticancer drug resistance in the human tumor cell lines of the National Cancer Institute drug screening program.

Xu Z, Chen ZP, Malapetsa A, Alaoui-Jamali M, Bergeron J, Monks A, Myers TG, Mohr G, Sausville EA, Scudiero DA, Aloyz R, Panasci LC.

Anticancer Drugs. 2002 Jun;13(5):511-9.


Application of high-throughput, molecular-targeted screening to anticancer drug discovery.

Shoemaker RH, Scudiero DA, Melillo G, Currens MJ, Monks AP, Rabow AA, Covell DG, Sausville EA.

Curr Top Med Chem. 2002 Mar;2(3):229-46. Review.


Expression of Bcl-2 family member Bid in normal and malignant tissues.

Krajewska M, Zapata JM, Meinhold-Heerlein I, Hedayat H, Monks A, Bettendorf H, Shabaik A, Bubendorf L, Kallioniemi OP, Kim H, Reifenberger G, Reed JC, Krajewski S.

Neoplasia. 2002 Mar-Apr;4(2):129-40.


Modulation of the multidrug-resistance phenotype by new tropane alkaloid aromatic esters from Erythroxylum pervillei.

Silva GL, Cui B, Chávez D, You M, Chai HB, Rasoanaivo P, Lynn SM, O'Neill MJ, Lewis JA, Besterman JM, Monks A, Farnsworth NR, Cordell GA, Pezzuto JM, Kinghorn AD.

J Nat Prod. 2001 Dec;64(12):1514-20.


Genomic-scale measurement of mRNA turnover and the mechanisms of action of the anti-cancer drug flavopiridol.

Lam LT, Pickeral OK, Peng AC, Rosenwald A, Hurt EM, Giltnane JM, Averett LM, Zhao H, Davis RE, Sathyamoorthy M, Wahl LM, Harris ED, Mikovits JA, Monks AP, Hollingshead MG, Sausville EA, Staudt LM.

Genome Biol. 2001;2(10):RESEARCH0041. Epub 2001 Sep 13.


Thymidine kinase, thymidylate synthase, and dihydropyrimidine dehydrogenase profiles of cell lines of the National Cancer Institute's Anticancer Drug Screen.

Grem JL, Danenberg KD, Behan K, Parr A, Young L, Danenberg PV, Nguyen D, Drake J, Monks A, Allegra CJ.

Clin Cancer Res. 2001 Apr;7(4):999-1009.

Supplemental Content

Support Center